Peppin
Prescription Drug Diversion P
Peppin
Prescription Drug Diversion P
- Broschiertes Buch
- Merkliste
- Auf die Merkliste
- Bewerten Bewerten
- Teilen
- Produkt teilen
- Produkterinnerung
- Produkterinnerung
Prescription Drug Diversion and Pain provides an interdisciplinary overview of medications used to treat chronic pain, specifically the benefits and risks that are posed by long-term opioids use. This book offers a single, comprehensive source for understanding the specialzied field of the opioid crisis and is a must-read for healthcare professionals, caregivers, policy makers, regulatory officials, law enforcement, and those in the pharmaceutical industryseeking to address the current and future opioid crisis.
Andere Kunden interessierten sich auch für
- Roger WoodruffPalliative Medicine126,99 €
- Neuropathic Pain204,99 €
- Practical Perioperative Transoesophageal Echocardiography176,99 €
- Heath B McAnallyPreoperative Optimization of the Chronic Pain Patient88,99 €
- John A KellumNeurocritical Care103,99 €
- Perioperative Pain Management for Orthopedic and Spine Surgery124,99 €
- Anesthesiology Critical Care Board Review204,99 €
-
-
-
Prescription Drug Diversion and Pain provides an interdisciplinary overview of medications used to treat chronic pain, specifically the benefits and risks that are posed by long-term opioids use. This book offers a single, comprehensive source for understanding the specialzied field of the opioid crisis and is a must-read for healthcare professionals, caregivers, policy makers, regulatory officials, law enforcement, and those in the pharmaceutical industryseeking to address the current and future opioid crisis.
Produktdetails
- Produktdetails
- Verlag: Oxford University Press, USA
- Seitenzahl: 272
- Erscheinungstermin: 1. August 2018
- Englisch
- Abmessung: 249mm x 175mm x 18mm
- Gewicht: 499g
- ISBN-13: 9780199981830
- ISBN-10: 0199981833
- Artikelnr.: 52157383
- Verlag: Oxford University Press, USA
- Seitenzahl: 272
- Erscheinungstermin: 1. August 2018
- Englisch
- Abmessung: 249mm x 175mm x 18mm
- Gewicht: 499g
- ISBN-13: 9780199981830
- ISBN-10: 0199981833
- Artikelnr.: 52157383
Dr. Peppin is board certified in Internal Medicine and pain medicine and is a certified EPEC trainer. Elected Fellow of the American College of Physicians, Kentucky Colonel in 2009 and PainWeek 2011 Clinician of the Year he has been active in the pain, palliative medicine, bioethics and internal medicine fields for over 20 years. Has published over 65 articles in the fields of pain management, palliative care and bioethics and edited books and given numerous lectures, papers and posters at conferences nationally and internationally. Dr. Peppin has been a reviewer for the Cochrane PaPaS group. Additionally he has been on editorial boards and is a reviewer for multiple journals. He currently has an active health care consulting business. Dr. Coleman's career began with fighting the French Connection, first in New York City, and then as Narcotics Attaché assigned to the American Embassy in Paris, France. His assignments carried him throughout the U.S. and around the world. He was appointed Assistant Administrator of the DEA in charge of operations, including the Office of Diversion Control. After retiring, Dr. Coleman founded the Prescription Drug Research Center LLC to assist companies in developing Abuse-Deterrent Drugs. Dr. Coleman was elected President of DrugWatch International, Inc., a global non-profit group dedicated to fighting drug abuse through education and prevention. Dr. Dineen is the director of the health law program at Creighton University School of Law. Before earning her JD and PhD (health care ethics), she practiced nursing in several practice areas, including working with many patients with chronic persistant pain. Her law practice included representing individual and institutional health care clients in regulatory and licensure matters. Dr. Dineen's current research focuses on the decision making in health policy and regulation and the impact on people with highly stigmatized conditions, such as high-impact chronic pain and addiction. Mr. Ruggles is a licensed attorney and current Ph.D. student. While earning his J.D. from Saint Louis University, he served the indigent population within the Archdiocese of Saint Louis through his work with Catholic Legal Assistance Ministry. Following law school and admittance to the Missouri Bar, he finished coursework towards a Ph.D. in health care ethics. His areas of interest include addiction, end of life issues, and the various other intersections of law and bioethics.
* John F. Peppin, John J. Coleman, and Kelly K. Dineen
* Chapter 1: Opioid Medications: Old Wine in New Bottles
* Timothy Atkinson, John J. Coleman, and Jeffrey Fudin
* Chapter 2: Legal Regulation of Prescription Opioids and Prescribers
* Kelly K. Dineen and Adam J. Ruggles
* Chapter 3: Monitoring Prescriptions, Third-Party Healthcare Payers,
Prescription Benefit Managers, and Private Sector Policy Options
* John J. Coleman
* Chapter 4: Whatever Happened to the Decade of Pain Control and
Research?
* John J. Coleman
* Chapter 5: Evaluation and Treatment of the Chronic Pain Patient:
Practice and Complexity
* John F. Peppin, Pravardhan Birthi, Bill H. McCarberg, and Yvonne
D'Arcy
* Chapter 6: An Overview of the Abuse Potential of Non-Opioids:
Sedatives, Hypnotics, and Stimulants
* Christopher M. Herndon and Kelly N. Gable
* Chapter 7: Psychiatry and Chronic Pain: An Associative Connection
* Hani Raoul Khouzam
* Chapter 8: Managing Pain in Patients with a History of a Substance
Use Disorder: Challenges and Opportunities
* Martin D. Cheatle
* Chapter 9: Special Populations
* Kelly K. Dineen
* Chapter 10: The Demise of Interdisciplinary Chronic Pain Management
and Its Relationship to the Scourge of Prescription Opioid Diversion
and Abuse
* Michael E. Schatman
* Chapter 11: Pain Management Assessment Beyond the Physician
Encounter: Urine Drug Monitoring and Patient Agreements
* Anand C. Thakur
* Epilogue
* John F. Peppin, John J. Coleman, and Kelly K. Dineen
* Chapter 1: Opioid Medications: Old Wine in New Bottles
* Timothy Atkinson, John J. Coleman, and Jeffrey Fudin
* Chapter 2: Legal Regulation of Prescription Opioids and Prescribers
* Kelly K. Dineen and Adam J. Ruggles
* Chapter 3: Monitoring Prescriptions, Third-Party Healthcare Payers,
Prescription Benefit Managers, and Private Sector Policy Options
* John J. Coleman
* Chapter 4: Whatever Happened to the Decade of Pain Control and
Research?
* John J. Coleman
* Chapter 5: Evaluation and Treatment of the Chronic Pain Patient:
Practice and Complexity
* John F. Peppin, Pravardhan Birthi, Bill H. McCarberg, and Yvonne
D'Arcy
* Chapter 6: An Overview of the Abuse Potential of Non-Opioids:
Sedatives, Hypnotics, and Stimulants
* Christopher M. Herndon and Kelly N. Gable
* Chapter 7: Psychiatry and Chronic Pain: An Associative Connection
* Hani Raoul Khouzam
* Chapter 8: Managing Pain in Patients with a History of a Substance
Use Disorder: Challenges and Opportunities
* Martin D. Cheatle
* Chapter 9: Special Populations
* Kelly K. Dineen
* Chapter 10: The Demise of Interdisciplinary Chronic Pain Management
and Its Relationship to the Scourge of Prescription Opioid Diversion
and Abuse
* Michael E. Schatman
* Chapter 11: Pain Management Assessment Beyond the Physician
Encounter: Urine Drug Monitoring and Patient Agreements
* Anand C. Thakur
* Epilogue
* John F. Peppin, John J. Coleman, and Kelly K. Dineen
* John F. Peppin, John J. Coleman, and Kelly K. Dineen
* Chapter 1: Opioid Medications: Old Wine in New Bottles
* Timothy Atkinson, John J. Coleman, and Jeffrey Fudin
* Chapter 2: Legal Regulation of Prescription Opioids and Prescribers
* Kelly K. Dineen and Adam J. Ruggles
* Chapter 3: Monitoring Prescriptions, Third-Party Healthcare Payers,
Prescription Benefit Managers, and Private Sector Policy Options
* John J. Coleman
* Chapter 4: Whatever Happened to the Decade of Pain Control and
Research?
* John J. Coleman
* Chapter 5: Evaluation and Treatment of the Chronic Pain Patient:
Practice and Complexity
* John F. Peppin, Pravardhan Birthi, Bill H. McCarberg, and Yvonne
D'Arcy
* Chapter 6: An Overview of the Abuse Potential of Non-Opioids:
Sedatives, Hypnotics, and Stimulants
* Christopher M. Herndon and Kelly N. Gable
* Chapter 7: Psychiatry and Chronic Pain: An Associative Connection
* Hani Raoul Khouzam
* Chapter 8: Managing Pain in Patients with a History of a Substance
Use Disorder: Challenges and Opportunities
* Martin D. Cheatle
* Chapter 9: Special Populations
* Kelly K. Dineen
* Chapter 10: The Demise of Interdisciplinary Chronic Pain Management
and Its Relationship to the Scourge of Prescription Opioid Diversion
and Abuse
* Michael E. Schatman
* Chapter 11: Pain Management Assessment Beyond the Physician
Encounter: Urine Drug Monitoring and Patient Agreements
* Anand C. Thakur
* Epilogue
* John F. Peppin, John J. Coleman, and Kelly K. Dineen
* Chapter 1: Opioid Medications: Old Wine in New Bottles
* Timothy Atkinson, John J. Coleman, and Jeffrey Fudin
* Chapter 2: Legal Regulation of Prescription Opioids and Prescribers
* Kelly K. Dineen and Adam J. Ruggles
* Chapter 3: Monitoring Prescriptions, Third-Party Healthcare Payers,
Prescription Benefit Managers, and Private Sector Policy Options
* John J. Coleman
* Chapter 4: Whatever Happened to the Decade of Pain Control and
Research?
* John J. Coleman
* Chapter 5: Evaluation and Treatment of the Chronic Pain Patient:
Practice and Complexity
* John F. Peppin, Pravardhan Birthi, Bill H. McCarberg, and Yvonne
D'Arcy
* Chapter 6: An Overview of the Abuse Potential of Non-Opioids:
Sedatives, Hypnotics, and Stimulants
* Christopher M. Herndon and Kelly N. Gable
* Chapter 7: Psychiatry and Chronic Pain: An Associative Connection
* Hani Raoul Khouzam
* Chapter 8: Managing Pain in Patients with a History of a Substance
Use Disorder: Challenges and Opportunities
* Martin D. Cheatle
* Chapter 9: Special Populations
* Kelly K. Dineen
* Chapter 10: The Demise of Interdisciplinary Chronic Pain Management
and Its Relationship to the Scourge of Prescription Opioid Diversion
and Abuse
* Michael E. Schatman
* Chapter 11: Pain Management Assessment Beyond the Physician
Encounter: Urine Drug Monitoring and Patient Agreements
* Anand C. Thakur
* Epilogue
* John F. Peppin, John J. Coleman, and Kelly K. Dineen